ETx-22: a novel nectin-4-directed antibody drug conjugate, demonstrates safety and potent antitumor activity in low nectin-4 expressing tumors.

MLA

Lopez, Marc, et al. “ETx-22: A Novel Nectin-4-Directed Antibody Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low Nectin-4 Expressing Tumors.” Cancer Research Communications, Oct. 2024. EBSCOhost, https://doi.org/10.1158/2767-9764.CRC-24-0176.

APA

Lopez, M., Crompot, E., Josselin, E., Farina, A., Rubis, M., Castellano, R., Fares, J., Wehbe, M., Collette, Y., Charafe-Jauffret, E., Blanchin, S., Romagne, F., Pálfi, A., Hechler, T., Pahl, A., Azim, H. A., Lhospice, F., Mamessier, E., Bertucci, F., … Olive, D. (2024). ETx-22: a novel nectin-4-directed antibody drug conjugate, demonstrates safety and potent antitumor activity in low nectin-4 expressing tumors. Cancer Research Communications. https://doi.org/10.1158/2767-9764.CRC-24-0176

Chicago

Lopez, Marc, Emerence Crompot, Emmanuelle Josselin, Anne Farina, Marion Rubis, Remy Castellano, Joanna Fares, et al. 2024. “ETx-22: A Novel Nectin-4-Directed Antibody Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low Nectin-4 Expressing Tumors.” Cancer Research Communications, October. doi:10.1158/2767-9764.CRC-24-0176.